BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 28933746)

  • 1. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
    Pang X; Fu H; Yang S; Wang L; Liu AL; Wu S; Du GH
    Molecules; 2017 Jul; 22(8):. PubMed ID: 28933746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of novel cinnamic acid-tryptamine hybrid for inhibition of acetylcholinesterase and butyrylcholinesterase.
    Ghafary S; Ghobadian R; Mahdavi M; Nadri H; Moradi A; Akbarzadeh T; Najafi Z; Sharifzadeh M; Edraki N; Moghadam FH; Amini M
    Daru; 2020 Dec; 28(2):463-477. PubMed ID: 32372339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases.
    Guo Y; Yang H; Huang Z; Tian S; Li Q; Du C; Chen T; Liu Y; Sun H; Liu Z
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of bakuchiol derivatives as multi-target agents for the treatment of Alzheimer's disease.
    Zhang XQ; Xiang YN; Qin T; Zou JP; Guo QW; Han ST; Zhang ZY; Liu WW; Ding G; Dong JQ; Shi DH
    Fitoterapia; 2024 Apr; 174():105867. PubMed ID: 38382891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DL0410, a novel dual cholinesterase inhibitor, protects mouse brains against Aβ-induced neuronal damage via the Akt/JNK signaling pathway.
    Zhou D; Zhou W; Song JK; Feng ZY; Yang RY; Wu S; Wang L; Liu AL; Du GH
    Acta Pharmacol Sin; 2016 Nov; 37(11):1401-1412. PubMed ID: 27498773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, biological evaluation and molecular docking of cyclic biguanidine compounds as cholinesterase inhibitors.
    Gungor O; Kose M
    J Biomol Struct Dyn; 2023 Dec; 41(20):10885-10899. PubMed ID: 36537267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of new N-benzyl-piperidine derivatives as multitarget-directed AChE/BuChE inhibitors for Alzheimer's disease.
    Conceição RAD; von Ranke N; Azevedo L; Franco D; Nadur NF; Kummerle AE; Barbosa MLC; Souza AMT
    J Cell Biochem; 2023 Nov; 124(11):1734-1748. PubMed ID: 37796142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies.
    Cavdar H; Senturk M; Guney M; Durdagi S; Kayik G; Supuran CT; Ekinci D
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):429-437. PubMed ID: 30734597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
    Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual binding site and selective acetylcholinesterase inhibitors derived from integrated pharmacophore models and sequential virtual screening.
    Gupta S; Mohan CG
    Biomed Res Int; 2014; 2014():291214. PubMed ID: 25050335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel tryptanthrin derivatives as selective acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
    Xia J; Dong S; Yang L; Wang F; Xing S; Du J; Li Z
    Bioorg Chem; 2024 Feb; 143():106980. PubMed ID: 38006789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unleashing new MTDL AChE and BuChE inhibitors as potential anti-AD therapeutic agents: In vitro, in vivo and in silico studies.
    Zaafar D; Elghazawy NH; Hassan A; Mahmoud MY; Bakr AF; Arafa RK
    Int J Biol Macromol; 2024 May; 268(Pt 1):131740. PubMed ID: 38653428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, In Vitro Biological Evaluation and In Silico Molecular Docking Study of Benzimidazole-Based Oxazole Analogues: A Promising Acetylcholinesterase and Butyrylcholinesterase Inhibitors.
    Hussain R; Rahim F; Ullah H; Khan S; Sarfraz M; Iqbal R; Suleman F; Al-Sadoon MK
    Molecules; 2023 Oct; 28(20):. PubMed ID: 37894494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives.
    Rampa A; Bisi A; Belluti F; Gobbi S; Valenti P; Andrisano V; Cavrini V; Cavalli A; Recanatini M
    Bioorg Med Chem; 2000 Mar; 8(3):497-506. PubMed ID: 10732965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.
    Campiani G; Fattorusso C; Butini S; Gaeta A; Agnusdei M; Gemma S; Persico M; Catalanotti B; Savini L; Nacci V; Novellino E; Holloway HW; Greig NH; Belinskaya T; Fedorko JM; Saxena A
    J Med Chem; 2005 Mar; 48(6):1919-29. PubMed ID: 15771436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of edaravone derivatives bearing the
    Zondagh LS; Malan SF; Joubert J
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1596-1605. PubMed ID: 32779503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-based modeling and 3D-QSAR for a quantitative production of the butyrylcholinesterase inhibitors based on genetic algorithm.
    Zaheer-ul H; Uddin R; Yuan H; Petukhov PA; Choudhary MI; Madura JD
    J Chem Inf Model; 2008 May; 48(5):1092-103. PubMed ID: 18444627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases.
    Saxena A; Fedorko JM; Vinayaka CR; Medhekar R; Radić Z; Taylor P; Lockridge O; Doctor BP
    Eur J Biochem; 2003 Nov; 270(22):4447-58. PubMed ID: 14622273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel acetylcholinesterase inhibitors designed by pharmacophore-based virtual screening, molecular docking and bioassay.
    Jang C; Yadav DK; Subedi L; Venkatesan R; Venkanna A; Afzal S; Lee E; Yoo J; Ji E; Kim SY; Kim MH
    Sci Rep; 2018 Oct; 8(1):14921. PubMed ID: 30297729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and molecular docking studies of some 4-phthalimidobenzenesulfonamide derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.
    Soyer Z; Uysal S; Parlar S; Tarikogullari Dogan AH; Alptuzun V
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):13-19. PubMed ID: 27766908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.